Knights of Columbus Asset Advisors LLC Cuts Position in Sanofi (NASDAQ:SNY)

Knights of Columbus Asset Advisors LLC cut its stake in Sanofi (NASDAQ:SNY) by 23.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,774 shares of the company’s stock after selling 1,184 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Sanofi were worth $182,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Boston Partners increased its holdings in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after acquiring an additional 2,501,073 shares during the period. Franklin Resources Inc. grew its stake in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after buying an additional 395,744 shares during the last quarter. Magnetar Financial LLC grew its stake in Sanofi by 104.3% during the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after buying an additional 1,705,148 shares during the last quarter. Natixis Advisors LLC grew its stake in Sanofi by 1.2% during the 4th quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company’s stock worth $140,350,000 after buying an additional 35,828 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Sanofi during the 4th quarter worth $135,933,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNY has been the topic of several research analyst reports. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday. They set a “neutral” rating and a $65.00 target price on the stock. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Stock Performance

Shares of SNY opened at $56.90 on Friday. The stock has a 50-day moving average of $54.55 and a two-hundred day moving average of $52.89. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a market cap of $144.40 billion, a P/E ratio of 22.85, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, research analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.